Pharmaceutical

EMA endorses AbbVie’s Skyrizi for ulcerative colitis

The EMA’s CHMP gave a positive opinion for Abbvie’s Skyrizi as the company bolsters its immunology pipeline.

Jun 2, 2024 - 04:00
EMA endorses AbbVie’s Skyrizi for ulcerative colitis
The EMA’s CHMP gave a positive opinion for Abbvie’s Skyrizi as the company bolsters its immunology pipeline.
Read the original article

Tags:

Previous Article

Dupixent gets closer to EU approval as the FDA delays its decision on COPD

Next Article

Manufacturing inspections down in China amid arrest fears and no access

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Launching pharmaceuticals in Belgium, the Netherlands, and Luxembourg: Opportunities and challenges

Launching pharmaceuticals in Belgium, the Netherlands, ...

Sep 21, 2023

STAT+: Beyond Wegovy and Ozempic: Biotechs vie for piece of red-hot weight loss market with novel strategies

STAT+: Beyond Wegovy and Ozempic: Biotechs vie for piec...

May 1, 2023

AMG-305 by Amgen for Breast Cancer: Likelihood of Approval

Jul 7, 2023